Jafron Biomedical Co.,Ltd.: history, ownership, mission, how it works & makes money

From a small R&D outfit founded in 1989 to a global blood‑purification leader selling into over 5,400 hospitals across more than 60 countries, Jafron Biomedical's rise is underscored by striking metrics: a market capitalization of about 15.88 billion yuan (Nov 2025), a workforce and partner network exceeding 2,100 combined, and a vertically integrated model built around its flagship HA hemoperfusion cartridges and newer BS bilirubin and DNA immunoadsorption columns; financials reinforce that trajectory - 2.68 billion yuan in revenue for 2024 (a 39.27% year‑over‑year increase) and a reported net profit of 820 million yuan, while insiders retain a controlling 50.26% stake and 774.36 million shares outstanding shape a stable ownership base that has supported ISO, CE and GMP certifications, international expansion with five global service centers, and the construction of the 95,318 m² Jinding Industrial Park aimed at scaling production and R&D for hemoadsorption technologies.

Jafron Biomedical Co.,Ltd. (300529.SZ): Intro

• Founded in 1989 as an R&D-focused enterprise specializing in blood purification products, initiating its long-term focus on extracorporeal treatment technologies.
• 2007: Expanded operations with a production and operations subsidiary established in Hubei Province to boost manufacturing capacity and regional reach.
• 2010: Achieved ISO 13485 certification, standardizing its medical device quality management system and enabling broader international market access.
• 2015: Launched the HA series disposable hemoperfusion cartridge-now the flagship product and a cornerstone of recurring-revenue consumables.
• 2018: Market capitalization reached approximately RMB 24.74 billion, reflecting rapid investor confidence and sector growth.
• By 2021: Networked 183 domestic offices in China and opened five global service centers, including presences in Vietnam, Europe and South America, expanding its international footprint.

• Publicly traded on the Shenzhen Stock Exchange (ticker: 300529.SZ), with a shareholder base composed of institutional investors, retail public float and company insiders/executives.
• Corporate governance follows PRC-listed company rules with an independent board and audit committee to comply with domestic/regulatory disclosure requirements.

• Core technology: hemoperfusion cartridges (HA series) using adsorbent materials to remove toxins, cytokines and specific molecules from blood-targeting sepsis, drug overdoses, liver failure support and inflammatory conditions.
• Product categories:
  • Disposable hemoperfusion cartridges (HA series)
  • Blood purification consumables and accessories
  • Related extracorporeal devices and integrated solutions (supporting pumps, lines)
  • Service, training and maintenance for clinical adoption
• Clinical deployment: hospital-based applications (ICU, nephrology, emergency), often integrated into multi-modal extracorporeal treatment protocols.

• Product sales: majority of revenue from disposable hemoperfusion cartridges and consumables-single-use products driving recurring sales.
• Equipment and device sales: capital equipment and auxiliary devices sold to hospitals and clinics, generating lower-frequency, higher-ticket revenue.
• After-sales services: maintenance, training, and technical support contracts that stabilize margins and customer retention.
• Geographic diversification: domestic hospital network sales plus exports via international service centers increasing overseas revenue share.

• Strong consumable-led model: single-use cartridges create predictable recurring revenue and inventory-driven gross margins.
• Regulatory and quality credentials: ISO 13485 and device approvals support hospital adoption and export compliance.
• Extensive domestic network plus targeted overseas service centers enabling scale and faster clinical uptake.

Jafron Biomedical Co.,Ltd. (300529.SZ): History

• IPO and listing: accelerated commercialization and international registrations after listing.
• R&D expansion: iterative improvements to sorbent materials and device integration for broader clinical applications.
• Market focus: China-first deployment with selective export partnerships to Asia and beyond.

• Mission: improve patient outcomes via blood purification technologies that reduce toxin load, inflammation and treatment burden.
• Strategy: combine proprietary sorbents with scalable manufacturing and hospital partnerships to expand indications and adoption.

• Product mechanism: sorbent cartridges and disposable sets capture circulating toxins, inflammatory mediators and specific molecules during extracorporeal blood treatment.
• Clinical integration: used alongside dialysis, CRRT or standalone hemoperfusion sessions in hospitals and specialty centers.

• Device sales: one-time or reusable platform sales to hospitals and clinics.
• Recurring consumables: primary revenue driver-disposable cartridges and disposables sold per treatment.
• Service and training: revenue from installation, clinical training and maintenance contracts.
• Export and licensing: incremental revenue from international distributors and technology partnerships.

Jafron Biomedical Co.,Ltd. (300529.SZ): Ownership Structure

• Mission: Provide professional blood-purification services and innovative hemoadsorption therapies to patients worldwide, enhancing quality of life.
• Core values: patient safety, clinical efficacy, regulatory compliance and technology-driven innovation.
• Strategic vision: establish a "product + services + finance + Internet" whole-value chain by 2025.

• CE marking for EU markets
• ISO certifications (quality management)
• Chinese GMP certification for medical device manufacture

• Products sold to over 5,400 large- and medium-sized hospitals
• Presence in more than 60 countries, including Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru and the United Arab Emirates

• Product sales: disposables and hemoadsorption cartridges for blood purification procedures sold to hospitals and dialysis centers.
• Clinical services: platform support, training and center-level service contracts that drive recurring consumable usage.
• Financial/Internet services: financing solutions and digital platforms to integrate care pathways and expand adoption.

Jafron Biomedical Co.,Ltd. (300529.SZ): Mission and Values

• End-to-end integration: in-house R&D, clinical validation, manufacturing, quality control and direct sales to hospitals and distributors.
• Flagship technology: the HA series disposable hemoperfusion cartridge - a hemoadsorption device designed to remove toxins, inflammatory mediators and endogenous/exogenous poisons in indications such as acute poisoning, sepsis-related cytokine storm and liver failure.
• Clinical collaboration: partnerships with hospitals and research institutions to generate clinical evidence, optimize protocols and support product adoption in intensive care and emergency settings.
• Global distribution: direct exports and distributor partnerships across Europe, Asia, Africa and South America, with established presence in markets including Germany, Thailand, Turkey and Chile.
• Manufacturing scale-up: investment in large, automated production bases to secure supply, reduce unit costs and meet regulatory standards for international markets.

• Jinding Industrial Park: a 95,318-square-meter complex (under development and expected to complete in 2023) intended to become one of the world's largest and most advanced blood purification equipment and consumable production bases.
• Workforce and partnerships: over 1,100 staff and a network of roughly 1,000 partners, including hospitals, distributors and research institutions, supporting commercialization, training and post-market services.
• Quality and compliance: manufacturing and quality systems designed to meet domestic CFDA/NMPA requirements and international standards for medical devices used in extracorporeal blood purification.

• Hemoadsorption innovation: continuous improvement of adsorbent materials and cartridge design to enhance adsorption capacity, biocompatibility and flow dynamics.
• Clinical evidence generation: randomized and observational studies to quantify outcomes (toxin clearance rates, cytokine reduction, organ function markers) and to expand labeled indications.
• Scale-enabled product development: leveraging large-scale manufacturing (Jinding Park) to iterate cost-effective single-use consumables while maintaining regulatory compliance.

• Device and consumable sales: primary revenue from single-use hemoperfusion cartridges and associated disposables sold to hospitals and distributors.
• Service and training revenue: clinical training, protocol development and after-sales technical support to institutional customers.
• Export sales: international distribution agreements and direct exports to multiple continents augment domestic sales and diversify market risk.
• R&D collaborations: funded clinical studies and co-development agreements with hospitals and research institutions that may include milestone or service fees.

• Hospital networks: deep clinical ties for pilot programs, product adoption and real-world evidence collection.
• International distributors: country-level partners handling regulatory registrations, logistics and local marketing.
• Academic collaborations: joint research projects to refine therapies, expand indications and publish clinical results.

Jafron Biomedical Co.,Ltd. (300529.SZ): How It Works

• Primary product lines: HA series hemoperfusion cartridges, BS bilirubin adsorption columns, DNA immunoadsorption columns.
• Adjacent product lines: hemodialysis concentrates, disinfectants, medical absorbable sutures and other disposables.
• Channels: direct sales to hospitals, distributors (domestic and international), OEM partnerships and tenders.
• Services & support: clinical training, maintenance/consumable replenishment and R&D collaborations with hospitals and research institutes.

• Recurring consumables: Hemoperfusion and adsorption cartridges require regular replacement, creating stable, high-margin recurring revenue.
• Product mix expansion: Addition of BS bilirubin adsorption and DNA immunoadsorption columns expands indications (liver support, immune-mediated conditions), increasing average selling price and addressable market.
• Geographic diversification: Sales to >5,400 hospitals across 60+ countries reduce single-market dependence and allow scale of manufacturing to lower unit costs.
• Complementary portfolio: Hemodialysis concentrates and medical consumables capture more of the hospital wallet and improve cross-sell opportunities.
• R&D-driven premiumization: New product introductions lift ASPs (average selling prices) and open new clinical pathways and reimbursement streams.

• Consumable attachment rate (cartridges per treated patient) - determines recurring revenue intensity.
• International revenue share - affects FX exposure and growth runway in developed markets.
• R&D spend and new approvals - pipeline conversion drives medium-term revenue expansion.
• Gross margin on cartridges vs. non-disposable products - indicates profitability of core business.

Jafron Biomedical Co.,Ltd. (300529.SZ): How It Makes Money

• Core products: hemoadsorption cartridges, dialysis consumables, and related blood purification disposables sold to hospitals and clinics.
• Recurring consumable sales: high-margin single-use cartridges and filters driving steady repeat revenue.
• Clinical services and training: hospital partnerships, on-site support, and O&M contracts augmenting product sales.
• International distribution: direct exports and local partners across >60 countries, expanding customer base and scale.
• Financial & digital initiatives: plans to integrate product + services + finance + Internet to create end-to-end value chain by 2025.